Search hospitals

>

Missouri

>

Springfield

CoxHealth South Hospital

Claim this profile

Springfield, Missouri 65807

Global Leader in Breast Cancer

Global Leader in Ovarian Cancer

Conducts research for Lung Cancer

Conducts research for Cancer

Conducts research for Breast cancer

391 reported clinical trials

9 medical researchers

Photo of CoxHealth South Hospital in SpringfieldPhoto of CoxHealth South Hospital in SpringfieldPhoto of CoxHealth South Hospital in Springfield

Summary

CoxHealth South Hospital is a medical facility located in Springfield, Missouri. This center is recognized for care of Breast Cancer, Ovarian Cancer, Lung Cancer, Cancer, Breast cancer and other specialties. CoxHealth South Hospital is involved with conducting 391 clinical trials across 534 conditions. There are 9 research doctors associated with this hospital, such as Jay W Carlson, Srikant Nannapaneni, Tania Papsdorf, MD, and Benjamin Lisle, MD.

Area of expertise

1

Breast Cancer

Global Leader

CoxHealth South Hospital has run 54 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV
2

Ovarian Cancer

Global Leader

CoxHealth South Hospital has run 47 trials for Ovarian Cancer. Some of their research focus areas include:

Stage IV
BRCA1 positive
Stage III

Top PIs

Clinical Trials running at CoxHealth South Hospital

Breast Cancer

Bladder Cancer

Lung Cancer

Breast cancer

Cancer

Prostate Cancer

Bladder Carcinoma

Ovarian Cancer

Kidney Cancer

Multiple Myeloma

Image of trial facility.

Nanosomal Docetaxel

for Triple Negative Breast Cancer

This trial tests a new, safer form of the cancer drug docetaxel, called Nanosomal Docetaxel Lipid Suspension (NDLS), in patients with advanced or spreading triple-negative breast cancer. NDLS aims to reduce side effects by using tiny fat particles. The drug works by stopping cancer cells from dividing and growing. Docetaxel is a widely used chemotherapy drug, and newer formulations like Nanosomal Docetaxel Lipid Suspension (NDLS) aim to improve its efficacy and reduce toxicity.

Recruiting

4 awards

Phase 3

13 criteria

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at CoxHealth South Hospital?

Where is CoxHealth South Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does CoxHealth South Hospital accept?

What awards or recognition has CoxHealth South Hospital received?